Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Assets: 2016-2025

Historic Assets for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $1.0 billion.

  • Tg Therapeutics' Assets rose 74.91% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 74.91%. This contributed to the annual value of $577.7 million for FY2024, which is 75.28% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Assets is $1.0 billion, which was up 45.89% from $702.6 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Assets ranged from a high of $1.0 billion in Q3 2025 and a low of $193.6 million during Q4 2022.
  • Moreover, its 3-year median value for Assets was $401.2 million (2024), whereas its average is $491.0 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 438.74% in 2021, then slumped by 49.01% in 2022.
  • Over the past 5 years, Tg Therapeutics' Assets (Quarterly) stood at $379.6 million in 2021, then slumped by 49.01% to $193.6 million in 2022, then surged by 70.27% to $329.6 million in 2023, then skyrocketed by 75.28% to $577.7 million in 2024, then surged by 74.91% to $1.0 billion in 2025.
  • Its Assets stands at $1.0 billion for Q3 2025, versus $702.6 million for Q2 2025 and $656.7 million for Q1 2025.